News

Ofev Approved in Europe for SSc-ILD Treatment in Adults

The European Commission has approved Ofev (nintedanib) to preserve lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This decision follows the recent recommendation from the Committee for Medicinal Products for Human Use, a branch of the European Medicines…

Canada Clears EHP-101, Possible Cannabidiol-derived Treatment

The active ingredient in EHP-101 — known as VCE-004.8, derived from synthetic cannabidiol — is not classified as a controlled substance under Canada’s Controlled Drug and Substance Act (CDSA),  the potential treatment’s developer, Emerald Health Pharmaceuticals, reported. VCE-004.8 is a non-reactive, non-psychotropic synthetic compound derived from cannabidiol, or CBD,…